Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer
RANDOMIZED PHASE II STUDY IN FIRST LINE HORMONAL TREATMENT FOR METASTATIC BREAST CANCER WITH EXEMESTANE OR TAMOXIFEN IN POSTMENOPAUSAL PATIENTS
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Listed as NCT00002777, this PHASE3 trial focuses on Breast Cancer and remains completed. Sponsored by European Organisation for Research and Treatment of Cancer - EORTC, it has been updated 6 times since 1996, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
May 1996
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- European Organisation for Research and Treatment of Cancer - EORTC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
's-Gravenhage (Den Haag, the Hague), Netherlands, Amersfont, Netherlands, Amsterdam, Netherlands, Antwerp, Belgium, Bangkok, Thailand, Bankstown, Australia, Bordeaux, France, Brisbane, Australia, Brussels (Bruxelles), Belgium, Caen, France and 36 more location s